Helen J. Blair

Newcastle Upon Tyne, ENG NE17RY, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

In Vivo Evaluation of a Self-Excitatory Near-Infrared ImmunoSCIFI Probe.

In Vivo Evaluation of a Self-Excitatory Near-Infrared ImmunoSCIFI Probe.

Journal: Bioconjugate chemistry
Published: January 07, 2026

Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Journal: Cancer cell international
Published: November 07, 2025

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma.

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma.

Journal: Neuro-oncology
Published: October 08, 2024

Fusion transcripts are present in early progenitor cells in KMT2A-rearranged B-ALL.

Fusion transcripts are present in early progenitor cells in KMT2A-rearranged B-ALL.

Journal: Leukemia
Published: October 27, 2023

A human mesenchymal spheroid prototype to replace moderate severity animal procedures in leukaemia drug testing.

A human mesenchymal spheroid prototype to replace moderate severity animal procedures in leukaemia drug testing.

Journal: F1000Research
Published: October 24, 2023

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1.

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1.

Journal: iScience
Published: October 23, 2023

Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Journal: Leukemia
Published: October 05, 2023

Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth.

Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth.

Journal: bioRxiv : the preprint server for biology
Published: July 28, 2023

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Journal: Cancer cell international
Published: July 26, 2023

Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth.

Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth.

Journal: Cell reports
Published: July 13, 2023

Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth.

Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth.

Journal: Nature communications
Published: May 02, 2023

The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.

The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.

Journal: HemaSphere
Published: February 07, 2023
Showing 1-12 of 40

Last Updated: 09/26/2026